Vivo Bio Tech Experiences Revision in Its Score Amid Strong Performance Indicators

Vivo Bio Tech, a microcap player in the Pharmaceuticals & Drugs sector, has recently seen an adjustment in its evaluation by MarketsMOJO. The stock's performance indicators reflect a notable improvement, particularly in its return on capital employed (ROCE), which has reached a commendable 14.57%. Additionally, the company's debt-equity ratio stands at a low 0.97 times, indicating a solid financial footing.
In the latest quarterly results, Vivo Bio Tech reported a profit before tax (PBT) of Rs 1.24 crore, showcasing a robust growth of 24.9%. The stock is currently positioned in a mildly bullish range, with technical indicators such as MACD and Bollinger Bands signaling positive momentum.

Despite a weak long-term fundamental strength, evidenced by a -3.21% compound annual growth rate (CAGR) in net sales over the past five years, the stock has generated a return of 15.98% over the last year, with profits soaring by 178.4%. Given these dynamics, Vivo Bio Tech has been added to MarketsMOJO's list, reflecting its evolving market position and performance metrics.